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Abstract
Aims Deciding if a diabetic foot ulcer is infected in a community setting is challenging without validated point-of-care
tests. Four inflammatory biomarkers were investigated to develop a composite algorithm for mildly infected diabetic foot
ulcers: venous white cell count, C-reactive protein (CRP) and procalcitonin, and a novel wound exudate calprotectin
assay. Calprotectin is a marker of neutrophilic inflammation.
Methods In a prospective study, people with uninfected or mildly infected diabetic foot ulcers who had not received oral
antibiotics in the preceding 2 weeks were recruited from community podiatry clinics for measurement of inflammatory
biomarkers. Antibiotic prescribing decisions were based on clinicians’ baseline assessments and participants were
reviewed 1 week later; ulcer infection was defined by clinicians’ overall impression from their two assessments.
Results Some 363 potential participants were screened, of whom 67 were recruited, 29 with mildly infected diabetic foot
ulcers and 38with no infection.One participantwithdrew early in each group.Ulcer areawas 1.32 cm2 [interquartile range
(IQR) 0.32–3.61 cm2] in infected ulcers and 0.22 cm2 (IQR 0.09–1.46 cm2) in uninfected ulcers. Baseline CRP for mild
infection was 9.00 mg/ml and 6.00 mg/ml for uninfected ulcers; most procalcitonin levels were undetectable. Median
calprotectin level in infected diabetic foot ulcers was 1437 ng/ml and 879 ng/ml in uninfected diabetic foot ulcers. Area
under the receiver operating characteristic curve for a composite algorithm incorporating calprotectin, CRP, white cell
count and ulcer area was 0.68 (95% confidence intervals 0.52–0.82), sensitivity 0.64, specificity 0.81.
Conclusions A composite algorithm including CRP, calprotectin, white cell count and ulcer area may help to
distinguish uninfected from mildly infected diabetic foot ulcers. Venous procalcitonin is unhelpful for mild diabetic foot
ulcer infection.
Diabet. Med. 00, 000–000 (2017)
Introduction
Diagnosis of diabetic foot ulcer infection continues to rely on
symptoms, principally pain, and signs, including erythema,
warmth, oedema and discharge. However, pain may be
absent due to concomitant neuropathy and signs may be
attenuated by vasculopathy [1]. Failure to treat mild infec-
tion with antibiotics risks progression to severe infection and
amputation. Conversely, unnecessary over-prescription of
antibiotics exposes the person to the risk of adverse effects,
increases the risk of subsequent infection with resistant
organisms, and contributes to increasing antimicrobial resis-
tance in society, one of the highest current public health
priorities [2]. The financial burden of diabetic foot ulcers and
associated amputations is large, approximately £650 million
in England in 2011, exceeding 0.6% of the total health
budget [3]. There are still no objective biomarkers of diabetic
foot ulcer infection available at the point of care, which is
particularly relevant because most diabetic foot ulcer care
occurs in the community [3].
A pilot study of 45 individuals with diabetic foot ulcers
reported that venous C-reactive protein (CRP) levels com-
bined with venous procalcitonin, another infection
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biomarker, may help in distinguishing between infected and
non-infected foot ulcers [4]. For a CRP cut-off value of
17 mg/L, negative predictive value was 0.91 and positive
predictive value was 0.83. Validated point-of-care tests for
CRP and other inflammatory biomarkers are now rapidly
entering the market, providing the potential for testing in the
community [5,6]. Calprotectin is a marker of neutrophilic
inflammation and therefore may be useful as a marker of
infection. It is currently largely used as a marker of
inflammatory bowel disease through testing faecal samples,
is available as a dipstick test, and is resistant to protease
degradation [7]. This makes it a candidate to directly assess
wound exudate, whose relatively high protease levels prevent
the use of several other candidate inflammatory biomarkers.
Diagnostic infection assays, including non-specific testing
of inflammatory markers, are likely to be most effective when
combined with optimal clinical assessment and patient
communication. For example, the use of a point-of-care test
for CRP combined with an educational intervention more
than halved antibiotic prescribing in primary care for lower
respiratory tract infections without compromising patient
safety [8].
The aim of our study was to determine the diagnostic
accuracy of a combined inflammatory biomarker algorithm
including venous white cell count, CRP and procalcitonin,
and wound exudate calprotectin levels in predicting diabetic
foot ulcer mild infection.
Patients and methods
Study design
The Updated List of Essential Items for Reporting Diagnostic
Accuracy Studies (STARD) extension of the EQUATOR
network has been followed to guide study reporting
(Appendix S1) [9]. A sequential recruitment observational
design was selected to provide proof of principle and
feasibility data, the intention being to use data from this
study to inform subsequent evaluations of the potential use
of point-of-care tests in future. Participants were recruited
from six community podiatry clinics in South Wales, UK and
the study received ethics approval from Wales Research
Ethics Committee 6 (ref 14/WA/0085). Inclusion criteria
were the presence of a full-thickness skin defect located distal
to the ankle that was assessed clinically as either uninfected
or mildly infected according to the Infectious Disease Society
of America International Working Group on the Diabetic
Foot (IDSA-IWGDF) classification system [10], in adults
aged at least 18 years who met World Health Organization
(WHO) diagnostic criteria for diabetes [11]. Exclusion
criteria were immunosuppression by medication or other
medical conditions, recent antibiotic treatment, pregnancy or
lactation, or IDSA-IWGDF moderate or severe diabetic foot
ulcer infection. During the first few weeks of recruitment it
was noted that receipt of antibiotics within the preceding
6 weeks excluded a high proportion of potential participants
and this criterion was reduced to 2 weeks, based on the
dynamics of inflammatory biomarker production in response
to infection [12].
It was anticipated that individuals with uninfected diabetic
foot ulcers would be more prevalent and easier to recruit,
and so it was prospectively decided to allow re-recruitment
of participants initially recruited with an uninfected diabetic
foot ulcer, if they subsequently presented with a mildly
infected diabetic foot ulcer. However, only data from their
infected diabetic foot ulcer presentation would be used in the
primary analysis of biomarker diagnostic accuracy, to avoid
the same participant being counted twice in analyses.
Infection definition
Our infection definition was based on the clinician’s
assessment 1 week after initial recruitment incorporating
any change from baseline, factoring in whether antibiotic
therapy had been received in the subsequent week. The
clinician obtained all the clinical information, including
measurement of ulcer area, vasculopathy and neuropathy,
while remaining blinded to assay results, including point-of-
care test results.
Data collection and study procedures
At baseline, experienced podiatrists provided a clinical
assessment of participants, including an overall assessment
of appearing well or unwell, checking for peri-ulcer ery-
thema, tenderness, warmth, lymphangitis and osteomyelitis.
Ankle brachial pressure indices (ABPIs) were recorded as a
measure of vasculopathy, with a level less than 0.9 consid-
ered abnormal, and duplex scanning was undertaken in those
with calcified vessels. Neuropathy was assessed by 10 g
monofilament in the relevant foot. If the diabetic foot ulcer
was judged to be infected at baseline on clinical grounds, oral
antibiotics and antimicrobial dressings were prescribed based
on local guidelines; oral antibiotics and antimicrobial
What’s new?
• Distinguishing between mild infection and no infection
in diabetic foot ulcers, a frequent position of equipoise
in antibiotic prescribing, is challenging in the absence of
objective evidence available at point of care.
• We developed a novel wound exudate calprotectin
assay which, when combined with venous C-reactive
protein, white cell count and ulcer area, provided a
diagnostic algorithm for diabetic foot ulcer infection.
• The combined algorithm has a specificity of 0.81 in
distinguishing mild infection from no infection in a
diabetic foot ulcer.
2
ª 2017 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.
DIABETICMedicine Use of inflammatory biomarkers for diabetic foot ulcer infections  J. R. Ingram et al.
dressings were not permitted in those whose diabetic foot
ulcer was judged to be uninfected.
Wound swabs, without debridement, were collected for
calprotectin measurement, as well as microscopy, culture and
antibiotic sensitivity analysis. Venous blood was sampled for
automated measurement of white cell count and CRP; serum
was stored at –80 °C for analysis of procalcitonin levels.
Quantification of procalcitonin was performed in duplicate
by ELISA (Abcam, UK, ab100630). CRP was also measured
from a pin prick of blood using a point-of-care instrument
(QuikRead go CRP, Orion Diagnostica, Finland); levels were
measured by a researcher and the result was not communi-
cated to the clinician until after they had provided their
overall assessment of ulcer infection status at the week 1 visit.
Participants were asked to return after 1 week for a repeat
clinical examination and to repeat sampling of venous blood,
wound exudate and point-of-care CRP testing. They also
kept a diary during the initial first week and three subsequent
weeks, recording ulcer symptoms, instigation of any antibi-
otics, adherence to treatment, other medications and dress-
ings required, quality of life [13], functional impairment [14]
and any ulcer complications, including hospitalization.
Calprotectin assay
Ulcer swabs were pre-processed by vortexing the head of the
swab in 3 ml of sterile saline for 5 s followed by sonication
for 5 min; the head of the swab was then centrifuged at
100 g for 1 min. Duplicate supernatant samples were
aliqoted and frozen at –80 °C for batched enzyme-linked
immunosorbent assay (ELISA) analysis within 1 year. A two-
site sandwich Calprotectin ELISA (MRP 8/14, S100A8/A9,
DRG Diagnostics) at an initial dilution of 1 : 2 was used,
absorbance being measured at 450 nm with a FLUOstar
Optima microplate reader (BMG LABTECH Ltd, UK).
Samples outside the upper limit of measurement were re-run
at dilutions of 1 : 20 or 1 : 200.
Sample size and statistical analysis
The largest previous study in the field recruited 23 partici-
pants with uninfected diabetic foot ulcers and 23 with
infected diabetic foot ulcers, with a designed clinical preva-
lence for infection of 50% [4]. Our intention was to exceed
this study size, ideally recruiting 50 participants with
uninfected diabetic foot ulcers and 50 with mildly infected
diabetic foot ulcers, providing 95% confidence intervals
(95% CI) of 0.77 to 0.96 around a positive predictive value
(PPV) of 0.90 for the diagnostic algorithm. Inflammatory
biomarker levels along with the gold standard dichotomous
classification of diabetic foot ulcer infection formed the
primary dataset. Cut-off points that optimized sensitivity,
specificity and the area under the receiver operating charac-
teristic curve (AUROCC) were calculated using Youden’s
index and the Euclidean distance from the upper left hand
corner to the co-ordinates of the curve [15]. Analyses to
obtain AUROCC utilized bootstrapping in Stata/IC 13.1
with 5000 repetitions and bias-corrected estimates are
reported.
Results
During a 12-month recruitment period, from October 2014
to September 2015, 363 potential participants were screened,
of whom 67 were recruited. A breakdown of reasons for
study non-recruitment is given in Table 1, with recent
antibiotic treatment being the most common cause. Some
screened participants were excluded because their ulcer was
not full thickness or was located proximal to the ankle, in the
context that the clinics assessed a spectrum of patients with
skin integrity problems. The primary dataset included 34
participants with uninfected diabetic foot ulcers and 27 with
mildly infected diabetic foot ulcers (Fig. 1). Table 2 details
the baseline characteristics of participants included in the
primary dataset. Median ulcer area for the uninfected group
was 0.22 cm2 [interquartile range (IQR) 0.09–1.46 cm2)
compared with 1.32 cm2 for mildly infected diabetic foot
ulcers (IQR 0.32–3.61 cm2).
Results for the inflammatory biomarker tests at baseline
are in Table 3, subdivided by their infection status as
determined by the study infection definition. The median
wound exudate calprotectin level in samples from mildly
infected diabetic foot ulcers was 1437 ng/ml (IQR 664–
6420 ng/ml) compared with 879 ng/ml (IQR 586–2674 ng/
ml) in uninfected ulcers. Venous procalcitonin results were
limited by 41 of the 59 baseline samples having a level below
the lower limit of assay detection, including 21 samples from
those with infected ulcers.
The inflammatory biomarker values were then combined
in logistic regression models as predictors of diabetic foot
ulcer infection, in each case creating a ‘likelihood score for
Table 1 Breakdown of reasons for study ineligibility in the 294
potential participants who were not recruited into the study. In some
individuals more than one reason was identified
Exclusion criterion
No. of
participants
Percentage
of ineligible
individuals
Antibiotic treatment in
last 2 weeks (post-Nov 2014)
82 28
Ulcer not full thickness/below
ankle
74 25
Moderate /severe infection 48 16
Not able to attend week
1 follow-up
37 13
Antibiotic treatment in last
6 weeks (pre-November 2014)
27 9
Not interested in participating 26 9
Immunosuppression 20 7
Unable to provide informed
consent
15 5
People without diabetes 11 4
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infection’ (LSI) from which receiver operating characteristic
curves could be plotted. Our original intention was to
combine point-of-care test CRP, white cell count, procalci-
tonin and calprotectin values, however, the lack of measur-
able procalcitonin levels led to exclusion of this variable from
the model. Participants lacking data for any of the required
variables were not included, and so the LSI for the remaining
three variables was based on 31 uninfected and 25 mildly
infected diabetic foot ulcer participants. The AUROCC was
0.63 (95% CI 0.47–0.78), indicating no benefit for predic-
tion of diabetic foot ulcer infection.
Having excluded procalcitonin from the combined algo-
rithm, we decided to substitute a clinical parameter as the
fourth variable. Ulcer area was chosen because results were
available for all participants, there was a six-fold difference
in the mean value between infected and uninfected ulcers,
and it is a straightforward measurement for clinicians to
obtain. Combination of the three remaining biomarkers,
point-of-care test CRP, white cell count and calprotectin
with baseline ulcer area produced a composite algorithm
demonstrating significant improvement in prediction of
diabetic foot ulcer infection, with an AUROCC of 0.68
(95% CI 0.52–0.82). Using Youden’s index and the
Euclidean distance from the upper left hand corner provided
a consistent cut-off point for LSI of 1.77, giving a sensitivity
of 0.64 and a specificity of 0.81, with a corresponding
positive predictive value of 0.73 and negative predictive
value of 0.75 (Appendix S2).
In terms of study safety, there were no serious adverse
events during the 4 weeks covered by trial diaries. Five of the
28 participants (18%) with uninfected diabetic foot ulcers
who returned their diary cards required oral antibiotics for
diabetic foot ulcer infection in the subsequent 3 weeks after
the week 1 assessment, compared with 15 of 23 with infected
diabetic foot ulcers (65%) who required additional antibi-
otics during this period.
Discussion
Our results show that an algorithm including white cell
count, CRP, wound exudate calprotectin and ulcer area has
an AUROCC which is insufficient to recommend its use
without further refinement. A sensitivity of 0.64 means that
if 100 people with a mildly infected diabetic foot ulcer were
tested, 64 would be correctly identified as having infection,
and there would be 36 false negatives. A specificity of 0.81
means that if 100 people with an uninfected diabetic foot
ulcer were tested, 81 would be correctly identified as having
no infection and there would be 19 false positives indicating
mild infection. Levels of the novel wound calprotectin
biomarker were nearly doubled in mild diabetic foot ulcer
infection, however, this result did not reach statistical
Screened = 363
Recruited = 67
Ineligible = 294
Week 0 uninfected = 35 Week 0 mildly infected = 28
Week 1 uninfected = 34
Lost to follow up = 1
Diary not returned = 6
Lost to follow up = 1
Week 1 mildly infected = 27
Diary not returned = 4
Uninfected Week 4 diary = 28 Infected Week 4 diary = 23
Re-recruited in 
infected group = 4
FIGURE 1 Participant flow diagram. A flow diagram summarizing participant recruitment into the INDUCE study. Uninfected or mildly infected
status is defined by the clinician’s overall clinical impression of the diabetic foot ulcer at week 1, incorporating response to antibiotics, if prescribed
at baseline, while blinded to all test results. Four participants who were recruited with uninfected ulcers subsequently re-presented with a mildly
infected ulcer and were recruited again, but their data is only counted once, for the episode of infection.
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significance. By contrast, venous procalcitonin levels were of
no value in detecting mild diabetic foot ulcer infection. The
parameters included in our algorithm are, or soon will be,
available at point of care, which is an important
consideration when most diabetic foot ulcer care occurs in
the community and antibiotic decisions have to be made
swiftly. We chose to restrict study participants to mild or no
ulcer infection because this distinction represents the greatest
challenge in diabetic foot ulcer antibiotic stewardship, in the
context that moderate to severe infection is straightforward
to diagnose from clinical parameters.
Venous procalcitonin or a combination of procalcitonin
and CRP have been used as biomarkers of diabetic foot ulcer
infection in several other studies. Jeandrot et al. calculated
an AUROCC of 0.95 (SD 0.029) for procalcitonin combined
with CRP [3], Uzun et al. demonstrated an AUROCC of
0.86 for procalcitonin alone [16], and Massara et al. found a
100-fold increase in procalcitonin levels between infected
and uninfected diabetic foot ulcers [17]. In comparing our
results with these other studies, it is possible that technical
issues using different assays might account for some of the
discrepancy, however participant selection criteria are the
most likely reason. Most of the other studies recruited from
hospitalized patients, with more severe diabetic foot ulcer
infections. Massara et al. did not restrict recruitment to mild
diabetic foot ulcer infection and 11 of the 15 patients in their
infected group were pyrexial, with a temperature > 38.5 °C,
graded as severe infection by the IDSA-IWGDF classification
system [17]. The increased severity of infection is reflected
by a mean CRP level of 121 mg/L, more than 10 times the
level in our patients judged to have infected diabetic foot
ulcers. Uzun et al. recruited participants who required
admission to hospital; 28 of the 49 were receiving antibiotics
at the time of admission and 7 of the 27 patients in the
infected group had MRI evidence of osteomyelitis, indicating
at least moderate infection [16]. Jeandrot et al. did use the
IDSA-IWGDF classification system and compared people
with mildly infected diabetic foot ulcers with those with
uninfected diabetic foot ulcers [4]. However, their study
population was again recruited in a hospital setting,
suggesting that more severe infection was likely, and people
with other inflammatory conditions were excluded, reducing
external validity.
We chose to screen and recruit sequential participants in a
community setting because this is where most people with
Table 2 Baseline characteristics of participants, subdivided by ulcer
infection status
Uninfected*
(n = 34)
Infected*
(n = 27)
Age at
recruitment
(years)
64.9 (11.0) 66.4 (14.4)
Male† 27 (79) 19 (70)
Ethnicity White
British/Welsh†
32 (94) 26 (96)
BMI (kg/m2) 33.6 (5.5) 28.3 (6.3)
Current smoker† 2 (6) 6 (22)
Ex-smoker† 18 (53) 13 (48)
Years since
diabetes
diagnosis
20.4 (9.9) 16.6 (11.3)
HbA1c
(mmol/mol)‡
64 (54–77) 68 (54–110)
HbA1c (%)‡ 8.0 (7.1–9.2) 8.4 (7.1–12.2)
At least
1 previous
ulcer in
past year
16 (47) 11 (43)
Current ulcer
area (cm2)‡
0.215 (0.090–1.463) 1.320 (0.320–3.610)
Current ulcer
duration
(weeks)‡
16.0 (8.4–73.5) 10.0 (1.1–66.0)
Previous
antibiotic
treatment of
current ulcer
23 (68) 13 (48)
Ankle brachial
pressure
index
abnormal in
ipsilateral
lower limb
8 of 23 (35) 8 of 15 (53)
Peripheral
neuropathy
in ulcerated foot
33 (97.1) 21 (77.8)
*Mean (SD) unless stated otherwise; †number (%) and ‡median
(25th to 75th percentile).
Table 3 Results of inflammatory biomarker tests, subdivided by ulcer infection status
Test Uninfected* Infected* AUROCC (95% CI)
White cell count (109 cells/L)† 7.43 (1.50) N = 32 8.15 (1.95) N = 27 0.62 (0.47–0.76)
Laboratory venous
C-reactive protein (mg/L)
4.5 (2.0–11.0) N = 32 7.0 (3.0–22.0) N = 27 0.62 (0.48–0.77)
Point-of-care venous
C-reactive protein (mg/L)
6.0 (5.0–15.5) N = 34 9.0 (5.0–17.0) N = 27 0.54 (0.39–0.69)
Venous procalcitonin (pg/ml) 21.8 (13.2–108)
N = 13 (20 below limit)
4.8 (1.96–14.1)
N = 4 (21 below limit)
Unable to calculate
Wound exudate
calprotectin (ng/ml)
879 (586–2674) N = 33 1437 (664–6420) N = 25 0.56 (0.41–0.71)
*Values are median (25th to 75th centiles), except †mean (SD).
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diabetic foot ulcers are treated, and where clinical equipoise
occurs most frequently in considering possible systemic or
topical antibiotic therapy for people with diabetic foot
ulcers. Biomarkers available at point of care in a community
setting have the greatest potential to avoid early infection
being missed and to support clinicians in avoiding inappro-
priate empirical antibiotic therapy in the absence of objective
evidence. In most people with moderate or severe infection
requiring hospitalization, clinical parameters such as overt
wound inflammation are sufficient to diagnose infection with
confidence and biomarkers are relatively redundant. Inflam-
matory biomarkers, in particular erythrocyte sedimentation
rate, may have a specific role to assist in the diagnosis of
occult osteomyelitis, which can be difficult to diagnose
clinically in the absence of immediate MRI resources [18].
In considering other strengths of our study, we selected an
infection definition that is more robust than relying on a
single clinical impression at one snap-shot in time. Our
definition was based on two separate clinical assessments,
1 week apart, allowing the clinician to integrate data
regarding the natural history of the ulcer and incorporating
response to antibiotic treatment, if given. All the clinicians
involved in the study were podiatrists who were experienced
in application of the IDSA-IWGDF classification system and
had completed an online educational tool to reinforce their
clinical skills. Our definition has not, however, been
subjected to validation studies to confirm that it performs
better than a single assessment. We avoided incorporating
microbiology results from ulcer swabs into our definition
because all wounds are colonized with organisms and the
method of sampling, comparing swabs with tissue samples, is
known to produce inconsistent results [19].
In terms of study limitations, our definition for infection
diagnosis has not been validated against the most robust gold
standard of a peri-ulcer tissue biopsy Gram stain and culture.
We chose not to incorporate a tissue biopsy in our study
because of the logistical challenge of performing biopsies in
the community and ethical considerations in terms of
enlarging the size of the diabetic foot ulcer in people with
uninfected or only mildly infected ulcers. Difficulty in
applying the gold standard for infection diagnosis in the
field of diabetic foot ulcers persists, which led to our
methodology of applying the IDSA-IWGDF criteria on two
separate occasions, one week apart, as a refinement when
using clinical parameters.
Regarding other study limitations, it would have been ideal
to measure toe pressures rather than ABPIs in our study
population, but ABPI measurement remained standard prac-
tice when our study was performed. In addition, it should be
noted that the dynamics of biomarker responses to infection
caused us to exclude people who had received oral antibiotics
within the preceding 2 weeks, resulting in 28% of screened
individuals being ineligible for the study. It follows that our
results are not generalizable to those who have received oral
antibiotics in the previous fortnight.
Building on the results from our calprotectin wound swab
assay, it may be that the focus of biomarker development for
diabetic foot ulcer infection should be directed towards
further wound fluid assays. It is perhaps unlikely that
circulating venous biomarkers are substantially raised by
mild infection in a foot ulcer, particularly when the vascular
supply to the foot is compromised. In addition, interference
from other comorbid inflammatory conditions is less likely to
affect the results. Other wound exudate biomarkers under
investigation include levels of lactate [20], interleukin-6 [21],
human neutrophil elastase and cathepsin G [22]. These could
be combined with calprotectin to produce a composite
wound exudate assay. Subsequent clinician education is
important to encourage behaviour change and to prevent
over-reliance on test results. Ultimately, an RCT is needed
utilizing a composite point-of-care test and accompanied by
an educational resource, to determine whether antibiotic
prescribing can be safely targeted for people with infected
diabetic foot ulcers, avoiding inappropriate antibiotic use in
people without diabetic foot ulcer infection.
In summary, our study demonstrated that a novel wound
exudate calprotectin biomarker shows promise in assisting
with the diagnosis of mild diabetic foot ulcer infection, a
scenario in which clinical equipoise is frequently encountered
regarding whether to offer antibiotic therapy. Combination
of calprotectin with venous white cell count and CRP, and
ulcer area improved diagnostic accuracy but the AUROCC of
0.68 remains insufficient to recommend the composite
algorithm without further refinement in a primary care
setting. Nevertheless, our algorithm’s specificity of 0.81
provides some much-needed objective evidence to help
clinicians avoid mass antibiotic prescribing in non-infected
diabetic foot ulcers, contributing to prevention of antimi-
crobial resistance.
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